Yet a team of researchers at Yale has shown that the effectiveness of progestin-therapy depends on whether a woman's endometriotic lesions have the progesterone receptor (PR) present. This study appears online in theJournal of Clinical Endocrinology & Metabolism.

The researchers tested the endometriotic lesions of 52 women who had undergone surgical evaluation for endometriosis at Yale New Haven Hospital for their PR status. They found a significant association between PR status and responsiveness to progestin-therapy. Those whose endometriotic lesions were PR-positive responded much better to the progestin-therapy, while those whose lesions were PR-negative found little relief from progestin-therapy alone.

从这些研究结果,该研究小组得出结论that knowing a woman's PR-status may help them develop a "novel, targeted, precision-based" approach to treating and managing endometriosis individually. "Receptor status in endometriosis could be used in a manner analogous to the use of estrogen/progesterone receptor status in breast cancer for tailoring hormonal-based regimens," said Dr. Valerie Flores, first author and clinical instructor at the Yale School of Medicine.

"Such an approach to endometriosis management would make trialing progestin-based therapy to determine response unnecessary," said Flores, "and would therefore minimize delays in providing the optimal medical therapy for each individual patient."

This study was funded by a grant from the National Institutes of Health. Other authors on this study include Arne Vanhie, Tran Dang, and Hugh Taylor.